A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
About the study
The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in Europe.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
* Patients will be eligible for inclusion if they fulfill all of the following criteria:
- Age ≥ 18 years at neratinib treatment initiation
- Having received at least one initial dose of neratinib as an extended adjuvant therapy for the treatment of early-stage HER2+ breast cancer, in the context of the EAP in Europe, and between August 01, 2017 and December 31, 2020
- Patients (or next of kin/legal representative, if applicable) who provide written informed consent or non-opposition.
EXCLUSION CRITERIA
Exclusion Criteria:
* N/A
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Breast Cancer,Adjuvant Therapy,HER2-positive Breast Cancer
Age
18+
Participants Needed
130
Est. Completion Date
Feb 28, 2023
Treatment Type
OBSERVATIONAL
Sponsor
Pierre Fabre Medicament
ClinicalTrials.gov NCT Identifier
NCT05599334
Study Number
NIS12501
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?